Phase IIB, randomized, multicenter clinical trial, continuation or non-continuation with 6 cycles of temozulomide after the first 6 cycles of standard first-line treatment in patients with glioblastoma
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: GEINO (SPANISH GROUP OF NEURONCOLOGY
- Phase: II
- Execution start: 20/01/2017
- End of execution: 31/12/2017
- PI: CARMEN SANCHEZ TORO